Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey

 

escrs app advert

Evaluation of clinical outcomes and astigmatism vector analysis of the monofocal Precizon toric IOL for astigmatism correction

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Toric Lenses & IOL Power Calculation

Venue: Poster Village: Pod 1

First Author: : A.Montesel SPAIN

Co Author(s): :    J. Alio del Barrio   A. Plaza-Puche   J. Alio                 

Abstract Details

Purpose:

To assess the effectiveness of a new design toric IOL

Setting:

Vissum Instituto Oftalmologico de Alicante, Alicante, Spain

Methods:

We perform a retrospective study on patients that had phacoemulsification for cataract or refractive lens exchange and implantation of the monofocal Precizon Toric Intraocular Lens (OPHTEC, The Netherlands). Inclusion criteria involved the presence of a regular refractive astigmatism of 1.50D or higher that was consistent with corneal toricity. Visual outcomes, astigmatic changes analyzed by Alpins vector analysis and IOL rotational stability were evaluated at one and six months post-operatively.

Results:

49 eyes of 38 patients were enrolled. At six months postoperatively, mean UDVA was 0.10 logMAR. BCVDA was 0.03 logMAR. The achieved SE refraction was within  0,50D of the target refraction in 93% of cases. Mean subjective astigmatism reduced from -2,59D (range: -1,5D to -9D) to -0,79D (range: -0,50D to -3D). The mean magnitude of the TIA was 2,44D (range: 1,39D to 8,81D), and the mean magnitude of the SIA was 1,23D (range: 0,09D to 5,29D). Mean Correction Index was 0,66 (range: 0,05 to 3,88). We reported a case of IOL rotation that required the realignment of the IOL.

Conclusions:

The clinical outcomes of the Precizon Toric IOL were satisfactory in them of visual acuity outcomes, predictability of refractive results, astigmatism reduction and lens stability.

Financial Disclosure:

None

Back to previous